← Leaderboards
Pranita Tamma
Johns Hopkins University
$1,875,341
Attributed
$1,875,341
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $416.9K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,875,341 · 4
By mechanism
R21$929,452 · 2
K23$733,720 · 1
K24$212,169 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Michael A. Carducci$23,642,506
- Kenneth J. Pienta$43,861,680
- Katherine Elizabeth Goodman$536,685
Others in their field
Other Emerging Leaders on “Mortality”
- Chanza Baytop · Westat, Inc.$271,217,917
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Greg Witham · Anp Technologies, Inc.$19,727,817
- Yunda Huang · Fred Hutchinson Cancer Center$19,033,873
- Barbara Halina Braffett · George Washington University$17,931,151
Research focus
MortalityLaboratoriesHospitalsAntibiotic TherapyPatient-Focused OutcomesK-Series Research Career ProgramsScienceResistance MechanismFutureMolecularEnsureResistanceInfectionComplexCarbapenemaseImproved OutcomeHourGenesMicrobiologyEpidemiologyAntibioticsGenotypeExhibitsEffective Therapy
Grant awards (9)
Advancing Mentorship at the Johns Hopkins Integrated Center for Combating Antimicrobial Resistant Bacteria$212,169
K24 · FY2025 · AI · contact PI
Identifying Optimal Antibiotic Treatment for Non-CTX-M-Producing ESBL Bloodstream Infections$204,688
R21 · FY2025 · AI · contact PI
Identifying Optimal Antibiotic Treatment for Non-CTX-M-Producing ESBL Bloodstream Infections$245,625
R21 · FY2024 · AI · contact PI
Modifiable Risk Factors for the Emergence of Resistance to Pseudomonas aeruginosa$203,381
R21 · FY2022 · AI · contact PI
Modifiable Risk Factors for the Emergence of Resistance to Pseudomonas aeruginosa$275,758
R21 · FY2021 · AI · contact PI
The Use of MALDI TOF for the Rapid Detection of Carbapenemases from Clinical Isolates$183,430
K23 · FY2020 · AI · contact PI
The Use of MALDI TOF for the Rapid Detection of Carbapenemases from Clinical Isolates$183,430
K23 · FY2019 · AI · contact PI
The Use of MALDI TOF for the Rapid Detection of Carbapenemases from Clinical Isolates$183,430
K23 · FY2018 · AI · contact PI
The Use of MALDI TOF for the Rapid Detection of Carbapenemases from Clinical Isolates$183,430
K23 · FY2017 · AI · contact PI